Full history for every metric is available with a Kvantra account
Jounce Therapeutics, Inc. (JNCE)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 72 | 65 | 148 | 62 | 27 | 82 | 82 |
| Operating profit | $m | -52 | -52 | |||||
| Net profit | $m | -16 | -27 | 57 | -44 | -91 | -51 | -51 |
| EPS reported | $ | -0.99 | -0.98 | |||||
| Operating cashflow per share | $ | -0.56 | -0.56 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -0.58 | -0.58 | |||||
| Free cash flow | $m | -30 | -30 | |||||
| Net debt | $m | -180 | -190 | |||||
| Book value equity | $m | 183 | 183 | |||||
| Book value per share | $ | 3.54 | 3.54 | |||||
| Number of shares | m | 51.68 | 51.68 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.31 | 0.54 | |||||
| P/S LTM | x | 0.70 | 1.21 | |||||
| P/FCF LTM | x | -1.93 | -3.32 | |||||
| EV/EBITDA LTM | x | 1.66 | 1.81 | |||||
| EV/Sales LTM | x | -1.01 | -1.10 | |||||
| Earnings Yield LTM | % | -88.77% | -52.41% | |||||
| FCF Yield | % | -51.95% | -30.11% | |||||
| Quality | ||||||||
| ROE | % | -27.81% | -25.03% | |||||
| ROIC | % | -27.05% | -27.05% | |||||
| Operating margin | % | -63.71% | -63.71% | |||||
| Gross margin | % | 100.00% | 100.00% | |||||
| FCF/Sales | % | -36.34% | -36.34% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +204.75% | +204.75% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.97 | -2.97 | |||||
| Net Debt/EBITDA | x | 2.80 | 2.80 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -312.97% | -191.54% | |||||
| Net debt/Equity | x | -0.98 | -1.04 | |||||
| Gross debt/equity | x | 0.05 | 0.05 | |||||
Company overview
Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors. The company is also progressing JTX-8064, an antibody designed to target leukocyte immunoglobulin like receptor B2 (LILRB2), a cell surface receptor found on macrophages. Additionally, JTX-1484 is under development, focusing on myeloid targets. Completing its innovative portfolio is JTX-1811, an anti-CCR8 monoclonal antibody precisely engineered to selectively reduce the presence of intra-tumoral T regulatory cells within the tumor's microenvironment. Jounce Therapeutics, Inc. was founded in 2012 and maintains its primary operational base in Cambridge, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jounce Therapeutics, Inc. (JNCE)
Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelimab, a monoclonal antibody presently in Phase II clinical trials. This therapeutic agent functions by binding to and activating the Inducible T cell CO-Stimulator (ICOS), a specific protein located on the surface of T cells within various solid tumors. The company is also progressing JTX-8064, an antibody designed to target leukocyte immunoglobulin like receptor B2 (LILRB2), a cell surface receptor found on macrophages. Additionally, JTX-1484 is under development, focusing on myeloid targets. Completing its innovative portfolio is JTX-1811, an anti-CCR8 monoclonal antibody precisely engineered to selectively reduce the presence of intra-tumoral T regulatory cells within the tumor's microenvironment. Jounce Therapeutics, Inc. was founded in 2012 and maintains its primary operational base in Cambridge, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free